logo

For the Inventor, By the Inventor

Ware, United Kingdom

David E Bays

USPTO Granted Patents = 29

Average Co-Inventor Count = 3.6

ph-index = 10

Forward Citations = 233(Granted Patents)


Location History:

  • Hertfordshire, GB (1984 - 1998)
  • Ware, GB (1983 - 2004)

Company Filing History:

goldMedal25 out of 1,168 
 
Glaxo Group Limited
 patents
silverMedal4 out of 2,198 
 
Smithkline Beecham Corporation
 patents

Years Active: 1983-2004

Loading Chart...
29 patents (USPTO):Explore Patents
1. 6677316 - Adenosine derivatives and methods of administration (2004-01-13),
2. 6610665 - 2-(purin-9-yl)-tetrahydrofuran-3, 4-diol derivatives (2003-08-26),
3. 6534486 - 2-(purin-9-yl)-Tetrahydrofuran-3,4-diol derivatives (2003-03-18),
4. 6492348 - Adenosine derivatives (2002-12-10),
5. 5719185 - Use for GABA agonists for treating emesis (1998-02-17),
6. 5270333 - Indole derivatives (1993-12-14),
7. 5229418 - Carboxylic acid derivatives (1993-07-20),
8. 5114950 - 5,6-dihydro-N-[(imidazol-4(or (1992-05-19),
9. 5045545 - [(Imidazol-4(and 5)-yl)methyl] tetracyclic ketones having 5-HT.sub.3 (1991-09-03),
10. 4997831 - Lactam derivatives (1991-03-05),
11. 4963546 - Ketone derivatives which are antagonists of 5-HT at 5-HT.sub.3 (1990-10-16),
12. 4923863 - Morpholine derivatives, pharmaceutical compositions and use (1990-05-08),
13. 4876267 - 5-Aminosulphoryl substituted indole derivatives (1989-10-24),
14. 4870096 - 5-substituted 3-aninoalkyl indoles (1989-09-26),
15. 4855314 - Indole derivatives (1989-08-08),

Title: The Innovations of Inventor David E Bays

Introduction:

David E Bays is a prolific inventor hailing from Ware, GB, with an impressive track record of 29 patents to his name. His innovative work in the field of adenosine derivatives and methods of administration has left a lasting impact on the medical industry.

Latest Patents:

One of David E Bays' latest patents involves adenosine derivatives and methods of administration for treating conditions such as ischemic heart disease, peripheral vascular disease, stroke, pain, CNS disorders, and sleep apnea. The compounds he has developed exhibit specific agonist activity at the adenosine A1 receptor, with minimal to no activity at the A3 receptor. These derivatives show promise in the treatment of various health issues.

In addition, David E Bays has also patented 2-(purin-9-yl)-tetrahydrofuran-3, 4-diol derivatives, which have shown efficacy in treating inflammatory diseases. The compounds, formulations, and administration methods outlined in this patent highlight his commitment to advancing medical treatments.

Career Highlights:

Throughout his career, David E Bays has made significant contributions to the field while working with renowned companies such as Glaxo Group Limited and SmithKline Beecham Corporation. His dedication to innovation and research has led to the development of groundbreaking technologies that have the potential to revolutionize healthcare.

Collaborations:

David E Bays has collaborated with esteemed professionals in the industry, including Colin F Webb and Roger Hayes. Their combined expertise has facilitated the successful development and implementation of novel medical solutions, benefitting patients worldwide.

Conclusion:

Inventor David E Bays' relentless pursuit of excellence and innovation has resulted in a remarkable portfolio of patents that have the potential to transform the healthcare landscape. His groundbreaking work serves as a testament to his ingenuity and dedication to improving the lives of individuals through pioneering medical advancements.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…